479690-10-3

Basic information

• Product Name: 3-fluoro-{4-[(6-(Methyloxy)-7-{[3-(4-Morpholinyl)propyl]oxy}-4-quinolinyl)oxy]phenyl}aMine
• Synonyms: 3-fluoro-{4-[(6-(Methyloxy)-7-{[3-(4-Morpholinyl)propyl]oxy}-4-quinolinyl)oxy]phenyl}aMine
• CAS NO: 479690-10-3
• Molecular Formula: C₂₃H₂₆FN₃O₄
• Molecular Weight: 427.4686432
• Mol File: 479690-10-3.mol
• Article Data: 40

Chemical Properties

• Boiling Point: 595.6±50.0 °C(Predicted)
• Appearance: /
• Density: 1.259±0.06 g/cm3(Predicted)
• PKA: 7.01±0.10(Predicted)
• CAS DataBase Reference: 3-fluoro-{4-[(6-(Methyloxy)-7-{[3-(4-Morpholinyl)propyl]oxy}-4-quinolinyl)oxy]phenyl}aMine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-fluoro-{4-[(6-(Methyloxy)-7-{[3-(4-Morpholinyl)propyl]oxy}-4-quinolinyl)oxy]phenyl}aMine(479690-10-3)
• EPA Substance Registry System: 3-fluoro-{4-[(6-(Methyloxy)-7-{[3-(4-Morpholinyl)propyl]oxy}-4-quinolinyl)oxy]phenyl}aMine(479690-10-3)

Safety Data

• Hazardous Substances Data: 479690-10-3(Hazardous Substances Data)

Upstream product

• 960299-44-9 4-(3-((4-(2-fluoro-4-nitrophenoxy)-6-methoxyquinolin-7-yl)oxy)propyl)morpholine 
• 110-91-8 morpholine 
• 479690-09-0 3-fluoro-4-{[7-(3-chloropropyl)-6-methoxy-4-quinolyl]oxy}nitrobenzene 
• 205448-32-4 4-chloro-6-methoxy-7-(3-morpholin-4-yl-propoxy)-quinoline 
• 399-96-2 4-amino-2-fluorophenol 
• 399-95-1 4-amino-3-fluorophenol 
• 1184831-17-1 1-[5-methoxy-4-(3-bromo-propoxy)-2-nitro-phenyl]-ethanone 
• 1219937-96-8 1-[5-methoxy-4-(3-morpholin-4-yl-propoxy)-2-nitro-phenyl]-ethanone 
• 1219937-97-9 1-[2-amino-5-methoxy-4-(3-morpholin-4-yl-propoxy)-phenyl]-ethanone 
• 1167053-13-5 6-methoxy-7-(3-morpholin-4-yl-propoxy)-quinolin-4-ol, sodium salt 
• 1160707-44-7 1-[4-(3-chloropropoxy)-5-methoxy-2-nitrophenyl]ethan-1-one 
• 1394166-08-5 (Ε)-1-(4-(3-chloropropoxy)-5-methoxy-2-nitrophenyl)-3-(dimethylamino)propyl-2-en-1-one 
• 1394166-09-6 6-methyloxy-7-(4-(3-chloropropoxy))-4-4-hydroxyquinoline 
• 498-02-2 1-(3-methoxy-4-hydroxyphenyl)ethanone 

Downstream Products

• 960299-46-1 methyl 1-(3-fluoro-4-(6-methoxy-7-(3-morpholinopropoxy)quinolin-4-yloxy)phenyl)-2-oxo-1,2-dihydropyridine-3-carboxylate 
• 849217-64-7 foretinib 
• 849221-53-0 cyclopropane-1,1-dicarboxylic acid {3-fluoro-4-[6-methoxy-7-(3-morpholin-4-yl-propoxy)-quinolin-4-ylamino]-phenyl}-amide (4-fluoro-phenyl)-amide 
• 1394165-61-7 N-(3-fluoro-4-((6-methoxy-7-(3-(morpholin-4-yl)propoxy)quinolin-4-yl)oxy)phenyl)-4-oxo-1-(2-(trifluoromethyl)phenyl)-1,4-dihydroquinoline-3-carboxamide 
• 1449763-30-7 phenyl 3-fluoro-4-(6-methoxy-7-(3-morpholinopropoxy)quinolin-4-yloxy)phenylcarbamate 
• 1449763-33-0 N¹-(3-fluoro-4-(6-methoxy-7-(3-morpholinopropoxy)quinolin-4-yloxy)phenyl)semicarbazide 
• 1428787-49-8 (E)-N⁴-(3-fluoro-4-(6-methoxy-7-(3-(morpholin-4-yl)propoxy)quinoline-4-yloxy)phenyl)-N¹-(benzylidene)semicarbazide 

Relevant articles and documents

QUINOLINE OR QUINAZOLINE COMPOUND AND APPLICATION THEREOF

The present invention relates to quinoline or quinazoline compound represented by the formula (I), a pharmaceutically acceptable salt thereof, a stereoisomer thereof, a prodrug molecule thereof, or a deuterated compound thereof. The compound of the presen

Discovery of 1,6-naphthyridinone-based MET kinase inhibitor bearing quinoline moiety as promising antitumor drug candidate

A series of 1,6-naphthyridinone-based MET kinase inhibitors bearing quinoline moiety in block A were designed and synthesized based on the structures of Cabozantinib and our reported compound IV. Extensive SAR and DMPK studies led to the identification of 20j, a potent and orally bioavailable MET kinase inhibitor with favorable kinase selectivity. More importantly, 20j exhibited statistically significant tumor growth inhibition (Tumor growth inhibition/TGI of 131%, 4/6 partial regression/PR) in the U-87 MG xeograft model, which is superior to that of Cabozantinib (TGI of 97%, 2/6 PR), and significantly better than that of compound IV (TGI of 15%, 0/6 PR) at the same dose (12.5 mg/kg). Combined with favorable in vitro potency, kinase selectivity, pharmacokinetic profile and in vivo efficacy, the promising antitumor drug candidate 20j has subsequently advanced into preclinical research.

Discovery of small molecule FLT3 inhibitors that are able to overcome drug-resistant mutations

Herein we report the discovery of 1-(5-(tert-butyl)isoxazol-3-yl)-3- (3-fluorophenyl)urea derivatives as new FLT3 inhibitors that are able to overcome the drug resistance mutations: the secondary D835Y and F691L mutations on the basis of the internal tandem duplications (ITD) mutation of FLT3 (FLT3-ITD/D835Y and FLT3-ITD/F691L, respectively). The most potent compound corresponds to 1-(5-(tert-butyl)isoxazol-3-yl)-3-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-3- fluorophenyl)urea (4d), which showed IC50s (half maximal inhibitory concentrations) of 0.072 nM, 5.86 nM and 3.48 nM against FLT3-ITD, FLT3-ITD/F691L and FLT3-ITD/D835Y, respectively. Compound 4d also showed good selectivity for FLT3 in a kinase profiling assay. Collectively, 4d could be a good lead compound and deserves further in-depth studies.